Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
PLoS One
2020 Jan 01;154:e0231700. doi: 10.1371/journal.pone.0231700.
Show Gene links
Show Anatomy links
Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations.
Gabriel FC
,
de Melo DO
,
Fráguas R
,
Leite-Santos NC
,
Mantovani da Silva RA
,
Ribeiro E
.
???displayArticle.abstract???
Depression affects over 300 million individuals worldwide and is responsible for most of the 800,000 annual suicides. Clinical practice guidelines (CPGs) for treatment of depression, founded on scientific evidence, are essential to improve patient care. However, economic and sociocultural factors may influence CPG elaboration, potentially leading to divergences in their recommendations. Consequently, we analyzed pharmacological recommendations for the treatment of depression from the most relevant CPGs. We included four CPGs with scores ≥ 80% for Domain 3 (rigor of development) on the Appraisal of Guidelines for Research and Evaluation and two other commonly used CPGs. The recommendations, their strengths, and the level of evidence were extracted from each CPG by two independent researchers and grouped as follows: (1) general recommendations for the pharmacological treatment for depression (suicide risk, acute treatment, continuation and maintenance phases, and treatment discontinuation); (2) treatment of non-responsive or partially responsive patients; and (3) treatment for subtypes of depression (chronic, psychotic, catatonic, melancholic, seasonal, somatic, mixed, and atypical). Only 50% of CPGs included recommendations for the risk of suicide associated with pharmacotherapy. All CPGs included serotonin selective reuptake inhibitors (SSRIs) as first-line treatment; however, one CPG also included agomelatine, milnacipran, and mianserin as first-line alternatives. Recommendations for depression subtypes (catatonic, atypical, melancholic) were included in three CPGs. The strength of recommendation and level of evidence clearly differed among CPGs, especially regarding treatment augmentation strategies. We conclude that, although CPGs converged in some recommendations (e.g., SSRIs as first-line treatment), they diverged in cardinal topics including the absence of recommendations regarding the risk of suicide associated with pharmacotherapy. Consequently, the recommendations listed in a specific CPG should be followed with caution.
???displayArticle.pubmedLink???
32315333
???displayArticle.link???PLoS One
Alonso-Coello,
The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies.
2010, Pubmed
Alonso-Coello,
The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies.
2010,
Pubmed
Armstrong,
Improvement evident but still necessary in clinical practice guideline quality: a systematic review.
2017,
Pubmed
Arnow,
Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
2015,
Pubmed
Arroll,
Antidepressants for treatment of depression in primary care: a systematic review and meta-analysis.
2016,
Pubmed
Barriocanal,
Quality assessment of peripheral artery disease clinical guidelines.
2016,
Pubmed
Burgers,
Characteristics of effective clinical guidelines for general practice.
2003,
Pubmed
Carvalho,
Augmentation strategies for treatment-resistant depression: a literature review.
2007,
Pubmed
Cipriani,
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
2018,
Pubmed
Collins,
Grand challenges in global mental health.
2011,
Pubmed
Eisinger,
Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer.
1999,
Pubmed
Fervers,
Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation.
2011,
Pubmed
Goldenberg,
Pharmaceutical approval update.
2009,
Pubmed
Guaiana,
Agomelatine versus other antidepressive agents for major depression.
2013,
Pubmed
Guaiana,
Amitriptyline for depression.
2007,
Pubmed
Hoffmann-Eßer,
Guideline appraisal with AGREE II: Systematic review of the current evidence on how users handle the 2 overall assessments.
2017,
Pubmed
Hoffmann-Eßer,
Guideline appraisal with AGREE II: online survey of the potential influence of AGREE II items on overall assessment of guideline quality and recommendation for use.
2018,
Pubmed
Hoffmann-Eßer,
Systematic review of current guideline appraisals performed with the Appraisal of Guidelines for Research & Evaluation II instrument-a third of AGREE II users apply a cut-off for guideline quality.
2018,
Pubmed
Hultcrantz,
The GRADE Working Group clarifies the construct of certainty of evidence.
2017,
Pubmed
Johnston,
Systematic reviews of clinical practice guidelines: a methodological guide.
2019,
Pubmed
Kennedy,
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.
2016,
Pubmed
Khoo,
Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
2015,
Pubmed
Lee,
Pediatric clinical practice guidelines for acute procedural pain: a systematic review.
2014,
Pubmed
Linde,
Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis.
2015,
Pubmed
Lopes,
Use of potentially inappropriate medications by the elderly at home.
2016,
Pubmed
Molino,
Factors Associated With High-Quality Guidelines for the Pharmacologic Management of Chronic Diseases in Primary Care: A Systematic Review.
2019,
Pubmed
,
Echinobase
Murray,
Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.
2015,
Pubmed
NULL,
2018,
Pubmed
Piano,
Guidelines for neuropathic pain management in patients with cancer: a European survey and comparison.
2013,
Pubmed
Raine,
Developing clinical guidelines: a challenge to current methods.
2005,
Pubmed
Rosebush,
Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam.
1990,
Pubmed
Saddichha,
Clinical practice guidelines in psychiatry: more confusion than clarity? A critical review and recommendation of a unified guideline.
2014,
Pubmed
Shiffman,
Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization.
2003,
Pubmed
Trivedi,
Medication augmentation after the failure of SSRIs for depression.
2006,
Pubmed
Ulrich,
Tranylcypromine in mind (Part I): Review of pharmacology.
2017,
Pubmed
Wijkstra,
Pharmacological treatment for psychotic depression.
2015,
Pubmed
Woolf,
Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines.
1999,
Pubmed
Woolf,
Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations.
2012,
Pubmed